Article Text

Download PDFPDF
Postoperative concurrent chronomodulated 5-fluorouracil/leucovorin infusion and pelvic radiotherapy for squamous cell carcinoma of the ovary arising from mature cystic teratoma
  1. V. T. Do1,
  2. G. M. Thomas1 and
  3. G. A. Bjarnason2
  1. 1Departments of Radiation Oncology and
  2. 2Medical Oncology, Toronto-Sunnybrook Regional Cancer Center, University of Toronto, Toronto, Ontario, Canada
  1. Address correspondence and reprint requests to: Professor Gillian M. Thomas, MD, BSc, FRCPC, Department of Radiation Oncology and Obstetrics and Gynecology, Toronto-Sunnybrook Regional Cancer Center, 2075 Bayview Avenue, Toronto ON M4N 3M5, Canada. E-mail: gillian.thomas{at}


Primary squamous cell carcinoma (SCC) of the ovary arising from mature cystic teratoma (MCT) is rare. Survival is very poor. Although different postoperative treatments have been tried, none appears to have influenced outcomes. A 44-year-old patient with FIGO stage IIB SCC of the ovary arising in MCT had exploratory laparotomy and left salpingo-oophorectomy, leaving macroscopic residual pelvic disease. Postoperative treatment consisted of a continuous concurrent chronomodulated infusion of 5-fluorouracil 150 mg/m2/day and leucovorin 10 mg/m2/day with 5 weeks of pelvic radiotherapy. Three years after initial surgery, she remains disease and complication free. Given this patient's unusually long disease-free survival and the efficacy of concurrent chemotherapy and radiotherapy in other SCCs, the concurrent circadian treatment approach used for this patient should be explored in other cases of SCC of the ovary.

  • chronomodulation
  • concurrent chemoradiotherapy
  • squamous cell carcinoma of the ovary

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.